Patten Group Inc. boosted its position in Pfizer Inc. (NYSE:PFE) by 42.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,413 shares of the biopharmaceutical company’s stock after purchasing an additional 3,673 shares during the period. Patten Group Inc.’s holdings in Pfizer were worth $486,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. 1 North Wealth Services LLC purchased a new position in Pfizer during the third quarter worth $29,000. Bourgeon Capital Management LLC purchased a new position in Pfizer during the third quarter worth $32,000. Salomon & Ludwin LLC increased its position in Pfizer by 362.7% during the third quarter. Salomon & Ludwin LLC now owns 893 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 700 shares in the last quarter. B & T Capital Management DBA Alpha Capital Management purchased a new position in Pfizer during the third quarter worth $36,000. Finally, Sageworth Trust Co purchased a new position in Pfizer during the third quarter worth $44,000. 70.21% of the stock is owned by hedge funds and other institutional investors.
PFE stock opened at $40.07 on Wednesday. Pfizer Inc. has a 52-week low of $33.97 and a 52-week high of $44.56. The stock’s fifty day simple moving average is $38.85 and its 200-day simple moving average is $38.20. The company has a quick ratio of 0.68, a current ratio of 0.90 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $218.54 billion, a price-to-earnings ratio of 13.36, a price-to-earnings-growth ratio of 4.18 and a beta of 0.65.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.13. Pfizer had a return on equity of 28.10% and a net margin of 30.57%. The business had revenue of $12.68 billion for the quarter, compared to analysts’ expectations of $12.37 billion. During the same quarter last year, the firm earned $0.78 earnings per share. The business’s revenue was down 4.6% on a year-over-year basis. As a group, analysts anticipate that Pfizer Inc. will post 2.97 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 31st will be issued a dividend of $0.38 per share. This is a boost from Pfizer’s previous quarterly dividend of $0.36. The ex-dividend date of this dividend is Thursday, January 30th. This represents a $1.52 annualized dividend and a dividend yield of 3.79%. Pfizer’s dividend payout ratio (DPR) is 48.00%.
PFE has been the subject of several recent research reports. Royal Bank of Canada initiated coverage on Pfizer in a research report on Monday, January 6th. They set an “outperform” rating and a $46.00 price target for the company. Bank of America initiated coverage on Pfizer in a research report on Wednesday, October 16th. They set a “neutral” rating and a $37.00 price target for the company. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Pfizer in a research report on Tuesday, October 29th. Zacks Investment Research raised Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 price target for the company in a research report on Tuesday, October 1st. Finally, ValuEngine upgraded Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. Nine equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $43.41.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Further Reading: How are dividend achievers different from dividend aristocrats?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.